secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001193125-24-189911
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics appoints Dr. Neely Mozaffarian to Board, expanding to 10 members
--------------------------------------------------------------------------------

- Dr. Mozaffarian appointed effective July 29, 2024, as Class II director and member of NCG and Science & Technology committees.
- Board increased from 9 to 10 directors; Mozaffarian fills newly created vacancy.
- Received option to purchase 80,000 shares at July 29 closing price, vesting monthly over 36 months.
- Mozaffarian is CMO at Atomwise with over 20 years immunology/autoimmunity R&D leadership.
- Appointment adds expertise in autoimmune disease and cell therapy development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/0001193125-24-189911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/d764342d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-189911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer